To determine the effect of chemotherapy followed by HDC plus IL-2 on the functional capabilities of NK cells in AML patients, we analyzed first the intracellular production of IFN-γ and of the marker CD107a that typically increases on the cell surface during degranulation. The gene discussed is IL2; the disease is acute myeloid leukemia.